These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 24304250)

  • 21. Aptamers used for biosensors and targeted therapy.
    Ning Y; Hu J; Lu F
    Biomed Pharmacother; 2020 Dec; 132():110902. PubMed ID: 33096353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
    Gilboa E; Berezhnoy A; Schrand B
    Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric aptamers in cancer cell-targeted drug delivery.
    Kanwar JR; Roy K; Kanwar RK
    Crit Rev Biochem Mol Biol; 2011 Dec; 46(6):459-77. PubMed ID: 21955150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses.
    Ciccone G; Ibba ML; Coppola G; Catuogno S; Esposito CL
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aptamer delivery of siRNA, radiopharmaceutics and chemotherapy agents in cancer.
    de Almeida CEB; Alves LN; Rocha HF; Cabral-Neto JB; Missailidis S
    Int J Pharm; 2017 Jun; 525(2):334-342. PubMed ID: 28373101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aptamer-Mediated Polymeric Vehicles for Enhanced Cell-Targeted Drug Delivery.
    Tan KX; Danquah MK; Sidhu A; Yon LS; Ongkudon CM
    Curr Drug Targets; 2018 Feb; 19(3):248-258. PubMed ID: 27321771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted delivery systems for oligonucleotide therapeutics.
    Yu B; Zhao X; Lee LJ; Lee RJ
    AAPS J; 2009 Mar; 11(1):195-203. PubMed ID: 19296227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospects for nucleic acid-based therapeutics against hepatitis C virus.
    Lee CH; Kim JH; Lee SW
    World J Gastroenterol; 2013 Dec; 19(47):8949-62. PubMed ID: 24379620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.
    Wang CW; Chung WH; Cheng YF; Ying NW; Peck K; Chen YT; Hung SI
    J Allergy Clin Immunol; 2013 Sep; 132(3):713-722.e11. PubMed ID: 23791505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic oligonucleotides.
    Goodchild J
    Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.
    Fu Z; Xiang J
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.
    Zhou J; Rossi JJ
    BioDrugs; 2012 Dec; 26(6):393-400. PubMed ID: 23046156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aptamer-based targeted therapy.
    Zhu G; Chen X
    Adv Drug Deliv Rev; 2018 Sep; 134():65-78. PubMed ID: 30125604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The application of aptamers in cancer research: an up-to-date review.
    Hu M; Zhang K
    Future Oncol; 2013 Mar; 9(3):369-76. PubMed ID: 23469972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue-Specific Delivery of Oligonucleotides.
    Xia X; Pollock N; Zhou J; Rossi J
    Methods Mol Biol; 2019; 2036():17-50. PubMed ID: 31410789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.
    Benedetto G; Vestal CG; Richardson C
    Target Oncol; 2015 Dec; 10(4):467-85. PubMed ID: 25989948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.
    Liang C; Guo B; Wu H; Shao N; Li D; Liu J; Dang L; Wang C; Li H; Li S; Lau WK; Cao Y; Yang Z; Lu C; He X; Au DW; Pan X; Zhang BT; Lu C; Zhang H; Yue K; Qian A; Shang P; Xu J; Xiao L; Bian Z; Tan W; Liang Z; He F; Zhang L; Lu A; Zhang G
    Nat Med; 2015 Mar; 21(3):288-94. PubMed ID: 25665179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
    Thiel KW; Hernandez LI; Dassie JP; Thiel WH; Liu X; Stockdale KR; Rothman AM; Hernandez FJ; McNamara JO; Giangrande PH
    Nucleic Acids Res; 2012 Jul; 40(13):6319-37. PubMed ID: 22467215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.